Quintessence Biosciences is working to improve the lives of cancer patients by developing new drugs based on EVade Ribonuclease technologies.
Lead Candidate, QBI-139
A Phase I trial of QBI-139 in cancer patients
with solid tumors is ongoing at the University of Wisconsin
Comprehensive Cancer Center (UWCCC)
in Madison and The University of Texas M. D. Anderson Cancer Center in Houston, Texas.
Information about the trial can be found at www.clinicaltrials.gov
(Clinical Trials.gov Identifier: NCT00818831).
Potential enrollees can contact the UWCCC Cancer
Connect (800-622-8922; 608-262-5223; email@example.com) or the M.D. Anderson Cancer Center (askMDAnderson at 1-877-MDA-6789; 713-792-1160) for
information. Quintessence Biosciences
will not directly enroll patients.
6.15.12Quintessence Biosciences Meeting with Partners at 2012 BIO International Convention (PDF)
Quintessence Biosciences (QuintBio) will be meeting with potential development partners at the BIO Business Forum at the 2012 BIO International Convention.
5.31.12Quintessence Biosciences Presents on Phase I trial of Human Ribonuclease Variant, QBI-139, at the American Society of Clinical Oncology Annual Meeting (PDF)
Quintessence today announced that the ongoing Phase I trial for their lead EVade™ Ribonuclease, called QBI-139, will be presented at the American Society of Clinical Oncology Annual Meeting.
4.19.12 Quintessence Biosciences Selected for Buzz of BIO at 2012 BIO International Convention (PDF)
Quintessence Biosciences has been chosen to participate in the Buzz of BIO, which allows industry leaders to select biotechnology companies to present at the Business Forum at the 2012 BIO International Convention.